281 related articles for article (PubMed ID: 38400661)
21. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ
Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
23. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
Alessi JV; Ricciuti B; Alden SL; Bertram AA; Lin JJ; Sakhi M; Nishino M; Vaz VR; Lindsay J; Turner MM; Pfaff K; Sharma B; Felt KD; Rodig SJ; Gainor JF; Awad MM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824161
[TBL] [Abstract][Full Text] [Related]
24. A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer.
Wu K; Fu Y; Zeng D; Chen T; Wang C; Jiang J
J Thorac Dis; 2022 Mar; 14(3):679-688. PubMed ID: 35399230
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of immune checkpoint inhibitors in advanced
Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
Front Immunol; 2022; 13():975246. PubMed ID: 36159795
[TBL] [Abstract][Full Text] [Related]
26. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S; Xiong A; Yu J; Wang X; Han B; Pan Y; Zhao J; Cheng Y; Hu S; Liu T; Li Y; Cheng Y; Feng J; Yi S; Gu S; Gao S; Luo Y; Liu Y; Liu C; Duan H; Wang S; Yang X; Fan J; Zhou C
Cancer Immunol Immunother; 2024 May; 73(7):124. PubMed ID: 38727837
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).
Xu Z; Li T; Hu X; Hao X; Xing P; Li J
Thorac Cancer; 2021 Sep; 12(17):2360-2368. PubMed ID: 34268872
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis.
Peng TR; Lin HH; Tsai FP; Wu TW
Thorac Cancer; 2021 Nov; 12(21):2873-2885. PubMed ID: 34545685
[TBL] [Abstract][Full Text] [Related]
29. Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis.
Cao R; Ma JT; Zhang SL; Sun L; Liu Y; Zhang XY; Jing W; Huang LT; Han CB
Cancer Med; 2019 Sep; 8(11):5033-5046. PubMed ID: 31297962
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
Sheng J; Li H; Yu X; Yu S; Chen K; Pan G; Xie M; Li N; Zhou Z; Fan Y
Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study.
Li R; Liang H; Li J; Shao Z; Yang D; Bao J; Wang K; Xi W; Gao Z; Guo R; Mu X
BMC Cancer; 2024 Jan; 24(1):107. PubMed ID: 38238648
[TBL] [Abstract][Full Text] [Related]
32. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
33. Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study.
Song L; Zhou F; Xu T; Zeng L; Xia Q; Wang Z; Deng L; Li Y; Qin H; Yan H; Huang Z; Mi J; Xu Q; Yang N; Zhou C; Zhang Y
BMC Cancer; 2023 May; 23(1):443. PubMed ID: 37189075
[TBL] [Abstract][Full Text] [Related]
34. JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Ramalingam SS; Thara E; Awad MM; Dowlati A; Haque B; Stinchcombe TE; Dy GK; Spigel DR; Lu S; Iyer Singh N; Tang Y; Teslenko I; Iannotti N
Cancer; 2022 Jan; 128(1):65-74. PubMed ID: 34478166
[TBL] [Abstract][Full Text] [Related]
35. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
36. A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
Salous T; Shukla NA; Althouse SK; Perkins SM; Furqan M; Leal T; Traynor AM; Feldman LE; Hanna NH; Durm GA
Cancer; 2023 Jan; 129(2):264-271. PubMed ID: 36420773
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China.
Yang W; Li T; Bai Y; Long Y; Gao M; Wang T; Jing F; Zhang F; Tao H; Ma J; Wang L; Hu Y
Front Oncol; 2023; 13():1147903. PubMed ID: 37124534
[TBL] [Abstract][Full Text] [Related]
38. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers.
Lo Russo G; Sgambelluri F; Prelaj A; Galli F; Manglaviti S; Bottiglieri A; Di Mauro RM; Ferrara R; Galli G; Signorelli D; De Toma A; Occhipinti M; Brambilla M; Rulli E; Triulzi T; Torelli T; Agnelli L; Brich S; Martinetti A; Dumitrascu AD; Torri V; Pruneri G; Fabbri A; de Braud F; Anichini A; Proto C; Ganzinelli M; Mortarini R; Garassino MC
ESMO Open; 2022 Dec; 7(6):100645. PubMed ID: 36455507
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
40. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
